Loading...
Market
How will Syndax's biotech sector ranking change by end of 2025?
2
Resolution / Starting Odds
No change • 25%
Improved by 1-5 ranks • 25%
Improved by 6-10 ranks • 25%
Improved by more than 10 ranks • 25%
Biotech sector rankings from financial and market analysis reports
Story
Syndax Secures FDA Approval for Revuforj®, First Menin Inhibitor for Relapsed Acute Leukemia, Shares Rise 4.3%
Nov 18, 2024, 06:16 PM
Syndax Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for its leukemia treatment, Revuforj® (revumenib). This drug is notable for being the first and only menin inhibitor approved for treating both adult and pediatric patients with relapsed or refractory acute leukemia featuring a KMT2A translocation. The approval marks a significant achievement for Syndax, especially following previous disappointments in other acute leukemia indications. Following the announcement, shares of Syndax ($SNDX) rose by 4.3% in pre-market trading.
View original story
Similar markets
Less than 5% growth • 25%
5% to 10% growth • 25%
10% to 20% growth • 25%
More than 20% growth • 25%
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%
Above industry average • 25%
Equal to industry average • 25%
Below industry average • 25%
Data unavailable • 25%
Outperforms sector • 25%
Matches sector performance • 25%
Underperforms sector • 25%
Significant volatility • 25%
Top 5 • 33%
Top 10 • 33%
Below top 10 • 33%
Significantly outperform • 25%
Slightly outperform • 25%
Match sector performance • 25%
Underperform • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Outside Top 50 • 25%
Outperform • 25%
Match • 25%
Underperform • 25%
Significantly Underperform • 25%
Top 50 • 25%
Top 100 • 25%
Top 200 • 25%
Below Top 200 • 25%
Yes • 50%
No • 50%
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Outside Top 30 • 25%